This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
PDGFRA K385 mutants in myxoid glioneuronal tumors promote receptor dimerization and oncogenic signaling
Scientific Reports Open Access 26 March 2024
-
Epidemiology and prognostic nomogram for chronic eosinophilic leukemia: a population-based study using the SEER database
Scientific Reports Open Access 26 February 2024
-
Overexpression of HOXA10 is associated with unfavorable prognosis of acute myeloid leukemia
BMC Cancer Open Access 22 June 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201–1214.
Schaller JL, Burkland GA . Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 2001; 3: 9.
Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH . Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359: 1577–1578.
Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101: 3391–3397.
Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102: 3093–3096.
Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 4660–4666.
Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104: 3038–3045.
Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 2008; 143: 707–715.
Helbig G, Stella-Holowiecka B, Majewski M, Calbecka M, Gajkowska J, Klimkiewicz R et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol 2008; 141: 200–204.
Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92: 1173–1179.
Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood 2007; 109: 4635–4640.
Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006; 30: 965–970.
Klion AD, Robyn J, Maric I, Fu W, Schmid L, Lemery S et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007; 110: 3552–3556.
Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M, Walz C et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 2011; 26: 162–164.
Fink SR, Belongie KJ, Paternoster SF, Smoley SA, Pardanani AD, Tefferi A et al. Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations. Leuk Res 2009; 33: 843–846.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author contributions
AP and AT contributed patients. AP, AD and AT reviewed, summarized and analyzed the clinical and laboratory data. RAK and RPK designed, performed and analyzed the FISH assays for FIP1L1-PDGFRA. CAH reviewed the bone marrow histology. All authors contributed towards writing the paper and approved the submitted draft.
Rights and permissions
About this article
Cite this article
Pardanani, A., D'Souza, A., Knudson, R. et al. Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome. Leukemia 26, 2439–2441 (2012). https://doi.org/10.1038/leu.2012.162
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.162
This article is cited by
-
Epidemiology and prognostic nomogram for chronic eosinophilic leukemia: a population-based study using the SEER database
Scientific Reports (2024)
-
PDGFRA K385 mutants in myxoid glioneuronal tumors promote receptor dimerization and oncogenic signaling
Scientific Reports (2024)
-
Myeloische/lymphatische Neoplasien mit Eosinophilie und Tyrosinkinase-Fusionsgenen
Die Onkologie (2023)
-
Diagnostik und Therapie von Eosinophilien
InFo Hämatologie + Onkologie (2021)
-
Overexpression of HOXA10 is associated with unfavorable prognosis of acute myeloid leukemia
BMC Cancer (2020)